Medifast, Inc.
NYSE:MEDPersonal Products & Services
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
Volume 0.09M
Average 0.21M
MED Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Medifast, Inc.NYSE: MED
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $76.04M fell 34.3% year over year, ahead of the -36.3% change in trailing-twelve-month revenue. Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at -37.7% a year.
Context
- Revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 1 analysts of $288.5M (-25.2%) for the fiscal year ending Dec 2026, a step up from the -36.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $76.04M+1.3% QoQ
- Last fiscal yearDec 2025
- $385.79M-36.0% YoY
- LTMMar 2026
- $346.1M-36.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -34.3% | -31.1% | +3.2 pp |
| 1 year | -36.0% | -25.2% | +10.7 pp |
| 3-year CAGR | -37.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 385.79M USD
- Year-over-year change
- -36.0%
- 4-year CAGR
- -29.1%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 385.79M | -36.0% |
| FY2024 | 2024-12-31 | 602.46M | -43.8% |
| FY2023 | 2023-12-31 | 1.07B | -32.9% |
| FY2022 | 2022-12-31 | 1.6B | +4.8% |
| FY2021 | 2021-12-31 | 1.53B | — |
Revenue vs competitors
How MED compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -36.3% is the 9th highest of 10, against a peer median of +0.8%.
- Over three fiscal years its annual growth of -37.7% compares with a peer median of -1.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM May 2026 | $979.93M USD | -10.1% | -8.1% | |
| LTM Dec 2025 | $765.74M USD | +17.6% | +13.1% | |
| LTM Mar 2026 | $604.02M USD | +3.0% | -0.6% | |
| FY2025 | HK$459.1M HKD | -8.9% | +0.2% | |
| LTM Mar 2026 | $346.1M USD | -36.3% | -37.7% | |
| LTM Feb 2026 | $333.46M USD | +2.4% | -11.6% | |
| LTM Jan 2026 | $287.75M USD | +30.8% | +12.5% | |
| LTM Mar 2026 | $252.46M USD | -1.2% | -7.4% | |
| LTM Mar 2026 | $89.46M USD | +0.8% | -2.6% | |
AIIORobo.ai Inc. | FY2025 | $950K USD | -92.1% | — |
| Peer median (excluding MED) | — | +0.8% | -1.6% | |
Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.53B | 1.6B | 1.07B | 602.46M | 385.79M |
| Cost of Revenue | 398.49M | 458.16M | 296.2M | 157.84M | 110.6M |
| Gross Profit | 1.13B | 1.14B | 775.85M | 444.62M | 275.19M |
| Gross Margin | 73.9% | 71.3% | 72.4% | 73.8% | 71.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Operating Expenses | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Depreciation & Amortization | 6.81M | 10.98M | 13.11M | 12.71M | 10.5M |
| EBITDA | 222.94M | 195.74M | 141.9M | 16.49M | 4.86M |
| EBITDA Margin | 14.6% | 12.2% | 13.2% | 2.7% | 1.3% |
| Operating Income | 216.24M | 184.81M | 126.4M | 2.88M | (14.21M) |
| Operating Margin | 14.2% | 11.6% | 11.8% | 0.5% | -3.7% |
| Interest Income | 0 | 0 | 2.49M | 4.8M | 5.52M |
| Interest Expense | 231K | 701K | 0 | 0 | 0 |
| Other Income / Expenses | (112K) | (747K) | 2.4M | 909K | 8.57M |
| Income Before Tax | 216.13M | 184.06M | 128.8M | 3.79M | (5.64M) |
| Pre-Tax Margin | 14.2% | 11.5% | 12.0% | 0.6% | -1.5% |
| Income Tax Expense | 52.1M | 40.49M | 29.38M | 1.7M | 13.03M |
| Net Income | 164.03M | 143.57M | 99.42M | 2.09M | (18.67M) |
| Net Margin | 10.7% | 9.0% | 9.3% | 0.3% | -4.8% |
| EPS (Basic) | 14.01 | 12.82 | 9.10 | 0.19 | (1.70) |
| EPS (Diluted) | 13.89 | 12.73 | 9.10 | 0.19 | (1.70) |
| Weighted Avg Shares | 11.71M | 11.2M | 10.88M | 10.93M | 10.98M |
| Weighted Avg Shares (Diluted) | 11.81M | 11.28M | 10.92M | 10.96M | 10.98M |
Medifast, Inc.
NYSE:MED
Intrinsic Alpha fair value
Locked
Current Price
$12.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.